ORIG3N raises $12.5 mln
ORIG3N Inc. said Wednesday that it closed a $12.5 million Series A financing co-led by Hatteras Venture Partners and Syno Capital. Also participating in the round was new investor, DEFTA Partners, and existing investors, Harris & Harris Group Inc., LabCorp, MGC Venture Partners and KTB-KORUS Fund. ORIG3N is a biotechnology company that is developing treatments for rare and genetically inherited diseases.
17 December 2015•5 mins read
